| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Letters to the Editor Articles
Editor:
My son was diagnosed in August 2007 with juvenile diabetes. I am a registered nurse and was devastated by the diagnosis because I was just completely paralyzed by the fear of potential complications. It was also a tremendous shock to be on the other side of health care – receiving information from hurried staff, including doctors, glancing at their watches while I asked one too many questions.
I, like the author of one of your articles this month, did a lot of research online and everything else I could read on the subject.
Eventually, I found out about a clinical trial by a company called Macrogenics, backed by the JDRF (Juvenile Diabetes Research Foundation) of an experimental drug for new onset diabetics that blocks the autoimmune attack.
After a tremendous amount of prayer and research, we decided to go ahead: My son took the drug, Teplizumab (MGA031). The drug was given via IV, and he was supposed to take it over 14 days. He only made it to eight before his liver enzymes tripled and he was pulled from the study. His enzymes returned to normal shortly thereafter.
I am writing to tell you that my son has not had to use insulin since November 27. Almost four full months insulin-free. No regular, no long-acting – nothing. (He was taking 17 units of Levemir at night and about 10 units of regular a day). We still take his blood sugar at least four times a day and we are careful about carbs (sugar, white flour especially). His last A1c was over two months ago and it was 5.6%.
He is still being monitored by Dr. Chayim Newmark (sub-investigator) and goes in for the required study follow-ups. His average blood sugar now is 100. His pediatric endocrinologist is, for some unknown reason, completely uninterested in the results of this study.
As I understand it, this drug has been purchased by Eli Lilly and more clinical trials will be conducted. The reason I am writing is twofold: 1) To share my excitement and this good news with someone in the field; and 2) to try to get the message out that this drug worked, and worked extremely well.
I believe that my son has been cured, I understand that all of the proper work must be done to make sure that this drug is safe, but I feel it is important to get the word out otherwise and was hoping for your input on this matter.
With much appreciation for the work you do,
Denise Smith
(Editor’s Note: Readers, have any of you or people you know had experiences with Teplizumab? If so, we’d like to hear from you.)
Categories: Letters to the Editor
Mar 21, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.